» Articles » PMID: 27778465

Improving the Health and Well-Being of Adults With Conditions of a Genetic Origin: Views from Professionals, Syndrome Support Groups and Parents

Overview
Date 2016 Oct 26
PMID 27778465
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Advances in medical genetics herald the possibility that health and social care services could be more responsive to the needs arising from a person's genotype. This development may be particularly important for those men and women whose learning disability (known internationally as intellectual disability) is linked to a neurodevelopmental condition of genetic origin.

Method: This possibility is tested through interviews with samples of (i) professional 'opinion former' with nationally recognised clinical and/or academic interests in learning disabilities and genetics; (ii) representatives of syndrome organisations prompting the interests of families where someone has a neurodevelopmental condition, and parent-members of these same organisations.

Results: The reporting and discussion of the interview data considers the possibility that notwithstanding the successes of the social model of disability, the health and wellbeing of people whose learning disability is associated with a neurodevelopmental condition could be better served by a more medicalised approach to their interests.

Conclusion: While a more medicalised approach to this populations' disabilities would appear to be beneficial, so long as it is focused on interventions to improve their lives rather than catalogues their deficiencies.

Citing Articles

'It's especially good just to know that you're not the only one': a qualitative study exploring experiences with online peer support programmes for the Fragile X community.

Haber T, Davies L, Hinman R, Bennell K, Bruce W, Jewell L J Intellect Disabil Res. 2024; 69(1):30-43.

PMID: 39322618 PMC: 11621584. DOI: 10.1111/jir.13188.


"Reasonable adjustments" under the UK's Equality Act 2010: An enquiry into the care and treatment to patients with intellectual disabilities in acute hospital settings.

Redley M, Lancaster I, Pitt A, Holland A, Thompson A, Bradley J J Appl Res Intellect Disabil. 2019; 32(6):1412-1420.

PMID: 31218787 PMC: 8045550. DOI: 10.1111/jar.12623.


Using Bayesian methodology to explore the profile of mental health and well-being in 646 mothers of children with 13 rare genetic syndromes in relation to mothers of children with autism.

Adams D, Hastings R, Alston-Knox C, Cianfaglione R, Eden K, Felce D Orphanet J Rare Dis. 2018; 13(1):185.

PMID: 30359268 PMC: 6203267. DOI: 10.1186/s13023-018-0924-1.


Genetic testing in intellectual disability psychiatry: Opinions and practices of UK child and intellectual disability psychiatrists.

Wolfe K, Stueber K, McQuillin A, Jichi F, Patch C, Flinter F J Appl Res Intellect Disabil. 2017; 31(2):273-284.

PMID: 28833975 PMC: 5836913. DOI: 10.1111/jar.12391.

References
1.
Woodcock K, Oliver C, Humphreys G . A specific pathway can be identified between genetic characteristics and behaviour profiles in Prader-Willi syndrome via cognitive, environmental and physiological mechanisms. J Intellect Disabil Res. 2009; 53(6):493-500. DOI: 10.1111/j.1365-2788.2009.01167.x. View

2.
Peters D, Yatsenko S, Surti U, Rajkovic A . Recent advances of genomic testing in perinatal medicine. Semin Perinatol. 2014; 39(1):44-54. PMC: 4883661. DOI: 10.1053/j.semperi.2014.10.009. View

3.
Evans W, Relling M . Moving towards individualized medicine with pharmacogenomics. Nature. 2004; 429(6990):464-8. DOI: 10.1038/nature02626. View

4.
. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014; 511(7510):421-7. PMC: 4112379. DOI: 10.1038/nature13595. View

5.
Miyamoto S, Miyake N, Jarskog L, Fleischhacker W, Lieberman J . Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry. 2012; 17(12):1206-27. DOI: 10.1038/mp.2012.47. View